Drug Profile
Research programme: transmucosal therapeutics - ULURU
Latest Information Update: 25 Sep 2009
Price :
$50
*
At a glance
- Originator ULURU
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Migraine; Pain
Most Recent Events
- 25 Sep 2009 Discontinued - Preclinical for Migraine in USA (Transmucosal)
- 25 Sep 2009 Discontinued - Preclinical for Pain in USA (Transmucosal)